EUCTR2009-015950-39-DE进行中（未招募）不适用
Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis - AMARA
Johann Wolfgang Goethe-Universität Frankfurt/M.0 个研究点开始时间: 2009年12月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and female patients, 18 to 75 years of age, with active rheumatoid arthritis (RA) who have had an inadequate response to disease modifying anti-rheumatic drugs (not more than 3 DMARDs including leflunomide, not more than one anti-TNF failure) and currently have active disease despite at least 3-month treatment with leflunomide. Active disease is defined as DAS 28 > 3.2 and at least swollen joint count (SJC) = 3 and tender joint count (TJC) = 3 included in the 28 joint count.
- •-Male and female patients with rheumatoid arthritis for at least 3 months diagnosed according to the revised 1987 ACR criteria for the classification of rheumatoid arthritis.
- •- Willingness and capability to give written informed consent, and willingness to participate and to comply with the study protocol.
- •- Not more than 2 non-biological DMARDs other than leflunomide in history, which are washed out at least 4 weeks prior to first rituximab infusion
- •- Inadequat response to no more than one anti-TNF treatment
- •- Previous use of anti-TNF therapy is allowed. Patient will only be allowed to be pre-treated with a maximum of two anti-TNF therapies and only one stopped due to inadequate response. The second anti-TNF could be stopped for instance due to
- •intolerance, e.g. injection site reactions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •-RA functional class IV: limited in ability to perform usual self-care, work, and other activities
- •- Male and female patients with other chronic inflammatory articular disease or systemic autoimmune disease
- •- Any active infection, a history of recurrent clinically significant infection, a history of recurrent bacterial infections with encapsulated organisms (Hepatitis B, C and HIV)
- •- Primary or secondary immunodeficiency
- •- Chronic, latent and acute infections of the lung
- •- Positive result of a Tb specific Interferon gamma release assay
- •- History of cancer with curative treatment not longer than 5 years ago except basal-cell carcinoma of the skin that had been excised
- •- Evidence of significant uncontrolled concomitant diseases or serious and / or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome
- •- Neuropathy that can interfere with filling out the patient's questionnaires
- •- History of a severe psychological illness or condition
- •- Known hypersensitivity to any component of the product or to murine proteins
- •- Severe heart failure (New York Heart Association Class III and IV) or severe, uncontrolled cardiac disease.
- •- Women lactating, pregnant, nursing or of childbearing potential with a positive pregnancy test or planned pregnancy.
- •- Women of childbearing potential without adequate contraception (medically acceptable methods (pearl index < 1) are contraceptive implant, contraceptive injection, intrauterine device (IUD), or oral contraceptives taken for at least 3 months, which the patient agrees to continue using during the study, or a double-barrier method which must consist of a combination of any of the following: diaphragma, cervical cap, condom, or spermicide)
- •- History of alcohol, drug or chemical abuse (defined as impaired / questionable reliability) as well as neurotic personality.
- •- Participation in another investigational study within 4 weeks prior to the screening visit.
- •- Previous treatment with any B-cell depleting agents including rituximab
- •- Intolerance to ingredients of rituximab or murine proteins
- •- Pre-treatment with abatacept, tocilizumab or other non anti-TNF biologicals.
- •-Inadequate response to more than one anti-TNF-therapy
- •-Pre-treatment of more than two anti-TNF, only one is allowed to be stopped due to inadequate response. The second anti-TNF could be stopped due to intolerance, e.g.
- •injection site reactions.
- •- Corticosteroids at doses exceeding 10 mg per day of prednisolone or equivalents within the last 2 weeks or corticosteroids at instable doses within the last 2 weeks
- •-Intolerance or contraindication to drugs required for the treatment of the side effects of rituximab
- •-Previous treatment with any investigational medicinal product within last 3 months prior to baseline
- •Receipt of a live vaccine within 4 weeks prior to treatment
- •Intra- articular or parenteral corticosteroids within 4 weeks prior to screening visit
- •Haemoglobin < 8.5 g / dl
- •-Neutrophil counts < 1.500 / µl
- •-Platelet count < 75.000 / µl
- •- Lower than 500 / µl (equivalent to 0,5 / nl) lymphocytes
- •-Serum creatinine > 1.4 mg / dl for women or 1.6 mg / dl for men
- •-AST or ALT > 2.5 times upper limit of normal
- •-IgG level < 5g/l
研究者
相似试验
已完成
3 期
Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT01244958Frank Behrens156
已完成
2 期
Phase II randomised study of fludarabine/cyclophosphamide combination with or without rituximab in patients with untreated mantle cell lymphomaMantle cell lymphomaCancerISRCTN81133184niversity College London (UK)151
进行中（未招募）
1 期
Phase II study. A combination of Lenalidomide and Rituximab as front line therapy for elderly frail patients (CGA) with Diffuse Large B-cells non-Hodgkin Lymphoma.Diffuse Large B-cells non-Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-003371-29-ITFONDAZIONE ITALIANA LINFOMI ONLUS68
已完成
2 期
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40
进行中（未招募）
1 期
Comparison of rituximab with lenalidomide or rituximab alone for patients with follicular lymphoma.EUCTR2010-021253-39-ITSAKK - GRUPPO SVIZZERO DI RICERCA CLINICA SUL CANCRO152